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Toxic epidermal necrolysis (TEN) is the most severe 
form of drug-induced skin reaction and includes 
denudation of >30% of total body surface area. The 
mechanism of disease is not completely understood, 
but immunologic mechanisms, cytotoxic reactions, and 
delayed hypersensitivity seem to be involved. Drug-
induced toxic epidermal necrolysis (TENS), also 
known as Lyell’s syndrome, remains one of the most 
dramatic dermatological emergencies characterized by 
extensive destruction of epidermis and mucosal 
epithelia that often can be caused by drugs. TEN 
affects between 0.4 and 1.5 cases per million people 
every year with a mortality rate between 15% to 40%, 
with a large portion of patients dying from infections 
or multi-organ failure.1-4 The pathogenesis of drug-
induced TEN is unknown, although several theories 
have been developed. Recent discoveries have shown 
that keratinocytes in TEN undergo apoptosis, not 
simply necrosis.5,6 Further research has elucidated that 
this apoptosis can be induced by interactions between 
cell surface death receptor Fas and its ligand, FasL or 
CD95L. The management of these patients is primarily 
supportive, although the use of corticosteroids and 
intravenous immunoglobulin (IVIG) therapy has been 
widely used with controversy. We report a case of 
risperidone induced toxic epidermal necrolysis with 
excellent response to corticosteroid. 
Case report 
A 45 yrs old woman with a long history of depressive 
illness was hospitalized in Benazir Bhutto Hospital, 
Rawalpindi for an acute episode of generalized body 
blisters formation. She reported no previous history of 
allergy to any medication upon admission. The patient 
developed hypovolemic shock requiring aggressive 
fluid resuscitation; CVP was 2cm of H2O. Laboratory 
findings revealed moderate hyperglycemia and raised 
CRP (70 mg/dl). The rest of the investigations were 
within normal limits. The patient started taking 
Risperidone one week back. On the third day, an 
erythematous rash and flaccid blisters appeared on her 
back and arm. The intake of medication was stopped 
immediately. The cutaneous rash progressed onto the 
trunk, face, and limbs reaching almost 52% of the body 
surface, blisters appeared progressively on the 
erythematous areas during the following 2 days. There 
was >30% skin epidermal detachment. A calculated 
SCORTEN value of 3 predicted a 35.8% mortality rate. 
Bilateral conjunctivitis and erosions of genital and oral 
mucosa also developed. The diagnosis of TEN was 
based on typical history and clinical findings of 
patient. Skin biopsy was planned but was delayed to 
avoid the risk of infections. The patient was placed on 
a fluidized bed and benefited from supportive and 
antiseptic measures. Systemic corticosteroids were 
given. Massive rehydration was undertaken with strict 
vital monitoring. Over the next 48 hours, there was 
involvement of >90% body surface area. The Nikolsky 
sign was positive. There was an erosive lesion of skin 
and mucosa involving eyes (Figures 1 & 2). She was 
discharged after 15 days with complete 
epithelialization. 
 
Figure 1&2: Toxic Epidermal Necrolysis 
Discussion 
The Stevens-Johnson syndrome and TEN represent the 
different degrees of acute mucocutaneous reaction that 
often can be caused by drugs.1 TEN is most commonly 
characterized by skin changes (scattered 2-ring target-
like lesion with a dark red center and a lighter red halo 
and macules with central blistering that can coalesce to 
larger areas of denuded skin), hemorrhagic mucositis 
(mouth, eyes, genitals, and respiratory tract), and 
systemic symptoms (fever, malaise, and possible 
internal organ involvement).3 SCORTEN, a TEN 
specific severity of illness scale, has been proven to be 
an accurate predictor of mortality in patients with TEN 
by evaluating 7 independent risk factors(age, presence 
of malignancy, body surface area involved, serum 
blood urea nitrogen level, glucose level, bicarbonate 
level, and heart rate).7 
Recent discoveries in the immunopathogenesis of TEN 
have shown that keratinocytes undergo apoptosis, not 
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simply necrosis, following different phases.10,11 Phase 1 
is determined by the immunogenic impact of 
xenobiotics. It involves a lack of balance between the 
activation and detoxification process in keratinocytes. 
Phase 2 corresponds to the early apoptosis. The 
generation of strongly electrophilic metabolites in TEN 
keratinocytes is thought to lead to disruption of the 
electron transfer chain in mitochondria. In a TEN 
keratinocyte it is likely that reactive oxygen species 
(ROS), acting as messengers, increase gene 
transcription of the TNF-a and CD95 proapoptotic 
systems.11In late apoptosis (Phase 3) the 
proinflammatory cytokine TNF-a is believed to act as 
an autocrine/paracrine factor on neighbouring 
keratinocytes, thus spreading epidermal destruction. 
In phase 4 cells with ruptured mitochondria are at risk 
of death through a nonapoptotic mechanism 
resembling necrosis.12 There is currently no specific 
treatment for TEN. Discontinuation of suspected drugs 
with supportive care (e.g. wound care, hydration, and 
nutritional support) forms the basis of treatment.4 
Intravenous immunoglobulin therapy (IVIG) is 
considered by many clinicians as a treatment option, 
blocking the blinding of CD95L.13 An updated review 
stratified results according to TEN and SJS, and 14 
studies in patients with TEN are evaluated. The 
majority of studies reported positive results, while 
three cohort studies did not observe statistically 
significant improvement with IVIG administration. 14 
In a sub-analysis of these controlled trials, mortality 
rates of patients receiving IVIG was 27% compared 
with 30% of predicted/ control group. Because of the 
heterogeneity of studies, a meta-analysis could not be 
conducted for IVIG in TEN or SJS. 
N-acetylcysteine (NAC) is a cysteine derivative 
precursor of GSH. Abnormal inherited metabolic 
pathways are presumed in some cases, which could 
lead to diminished detoxifying capacity. 
Administration of N-acetylcysteine enhances the 
oxidant buffering capacity of glutathione and inhibits 
nuclear factors kappa B, a transcription factor induced 
by TNF-a and interleukin-6. Few patients have been 
successfully treated with high dose intravenous NAC 
in open-label studies.15,16 Further studies are required 
to confirm the beneficial therapeutic effect of NAC in 
TEN. In our patient, a good response was achieved 
with corticosteroids with supportive care showing the 
potential beneficial effect in TEN. Different studies 
had used thalidomide, cyclosporine, infliximab, 
azathioprine, methotrexate, cyclophosphamide, and 
plasmapheresis but were limited data to be 
recommended as first-line treatment.17,18 It is important 
to identify patients at a risk to avoid delaying therapy. 
It is suggested that several molecular targets that block 
different apoptosis/necrosis pathways should be 
attacked simultaneously to achieve optimal efficacy in 
the treatment of TEN. 
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